- Home
- HRMY vs MIRM Comparison
HRMY vs MIRM Comparison
Compare HRMY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- MIRM
- Stock Information
- Founded
- HRMY 2017
- MIRM 2018
- Country
- HRMY United States
- MIRM United States
- Employees
- HRMY N/A
- MIRM N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- MIRM Health Care
- Exchange
- HRMY Nasdaq
- MIRM Nasdaq
- Market Cap
- HRMY 1.8B
- MIRM 2.5B
- IPO Year
- HRMY 2020
- MIRM 2019
- Fundamental
- Price
- HRMY $34.43
- MIRM $51.94
- Analyst Decision
- HRMY Strong Buy
- MIRM Strong Buy
- Analyst Count
- HRMY 9
- MIRM 9
- Target Price
- HRMY $54.44
- MIRM $66.22
- AVG Volume (30 Days)
- HRMY 594.8K
- MIRM 460.4K
- Earning Date
- HRMY 08-05-2025
- MIRM 08-06-2025
- Dividend Yield
- HRMY N/A
- MIRM N/A
- EPS Growth
- HRMY 13.13
- MIRM N/A
- EPS
- HRMY 2.62
- MIRM N/A
- Revenue
- HRMY $744,852,000.00
- MIRM $379,251,000.00
- Revenue This Year
- HRMY $20.33
- MIRM $35.83
- Revenue Next Year
- HRMY $17.67
- MIRM $16.83
- P/E Ratio
- HRMY $13.30
- MIRM N/A
- Revenue Growth
- HRMY 20.62
- MIRM 69.31
- 52 Week Low
- HRMY $26.47
- MIRM $36.20
- 52 Week High
- HRMY $41.61
- MIRM $54.78
- Technical
- Relative Strength Index (RSI)
- HRMY 64.26
- MIRM 64.41
- Support Level
- HRMY $33.76
- MIRM $52.25
- Resistance Level
- HRMY $35.08
- MIRM $54.78
- Average True Range (ATR)
- HRMY 0.87
- MIRM 1.61
- MACD
- HRMY 0.34
- MIRM 0.10
- Stochastic Oscillator
- HRMY 92.43
- MIRM 73.08
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.